Catalyst Pharmaceuticals, Inc. $CPRX Shares Sold by Royce & Associates LP

Royce & Associates LP reduced its stake in shares of Catalyst Pharmaceuticals, Inc. (NASDAQ:CPRX) by 6.1% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,910,767 shares of the biopharmaceutical company’s stock after selling 124,198 shares during the quarter. Royce & Associates LP owned about 1.55% of Catalyst Pharmaceuticals worth $44,597,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of CPRX. Rothschild Investment LLC raised its stake in Catalyst Pharmaceuticals by 1,085.7% during the 3rd quarter. Rothschild Investment LLC now owns 1,660 shares of the biopharmaceutical company’s stock worth $33,000 after acquiring an additional 1,520 shares in the last quarter. Advisory Services Network LLC acquired a new stake in Catalyst Pharmaceuticals during the 3rd quarter worth $39,000. Quarry LP acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at $40,000. Clearstead Advisors LLC increased its stake in Catalyst Pharmaceuticals by 192.9% in the fourth quarter. Clearstead Advisors LLC now owns 1,772 shares of the biopharmaceutical company’s stock valued at $41,000 after purchasing an additional 1,167 shares during the period. Finally, Financial Life Planners acquired a new position in Catalyst Pharmaceuticals in the third quarter valued at $42,000. 79.22% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Pharmaceuticals Price Performance

Shares of NASDAQ CPRX opened at $31.26 on Tuesday. Catalyst Pharmaceuticals, Inc. has a 12-month low of $19.05 and a 12-month high of $32.56. The company has a market capitalization of $3.83 billion, a PE ratio of 17.97, a price-to-earnings-growth ratio of 0.91 and a beta of 0.72. The firm’s 50-day moving average is $26.97 and its two-hundred day moving average is $24.78.

Wall Street Analyst Weigh In

A number of research analysts have commented on CPRX shares. Weiss Ratings restated a “buy (b-)” rating on shares of Catalyst Pharmaceuticals in a research note on Friday, March 27th. Citigroup lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “neutral” rating and dropped their price objective for the company from $35.00 to $31.50 in a research note on Friday, May 8th. Wall Street Zen lowered shares of Catalyst Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Saturday, May 9th. Truist Financial raised shares of Catalyst Pharmaceuticals to a “strong-buy” rating in a report on Wednesday, March 25th. Finally, Zacks Research downgraded shares of Catalyst Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Monday, May 18th. Two investment analysts have rated the stock with a Strong Buy rating, one has issued a Buy rating and five have assigned a Hold rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $32.17.

Catalyst Pharmaceuticals Profile

Catalyst Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for patients living with rare neuromuscular, neurological and metabolic diseases. The company’s mission centers on delivering safe and effective treatments that address unmet medical needs in small patient populations.

The company’s lead product is Firdapse® (amifampridine phosphate), a treatment approved by the U.S. Food and Drug Administration for adults with Lambert-Eaton Myasthenic Syndrome (LEMS).